In addition, activating KRAS mutations in non-small cell lung cancer (NSCLC), pancreatic and intestinal cancers enhance serine synthesis by increasing transcription of NRF2, a master regulator that promotes serine/glycine synthesis enzyme gene expression through ATF4 activation [9–11]. The gene discussed is ATF4; the disease is non-small cell lung carcinoma.